7 New Blockbuster Drugs to Watch in 2016
7 New Blockbuster Drugs to Watch in 2016 - Fortune
This year's slate of new drug launches features at least seven drugs expected to hit blockbuster status within the next five years, according to a study by ...
7 New Blockbuster Drugs to Watch in 2016 - Yahoo Finance
7 New Blockbuster Drugs to Watch in 2016 · 1. Intercept Pharmaceuticals and Sumitomo Dainippon Pharma · 2020 Forecast Sales: · 2. Gilead Sciences ...
Seven $1 billion-plus drugs seen reaching market in 2016 | Reuters
The two top hits of 2016 are tipped to be Intercept Pharmaceuticals' chronic liver disease drug obeticholic acid, with a consensus sales ...
7 New Blockbuster Drugs of 2016 - LinkedIn
1. Intercept Pharmaceuticals and Sumitomo Dainippon Pharma Drug: Obeticholic acid Indication: Chronic liver diseases, primarily primary ...
Blockbuster Watch: Key Market Entrants for 2016
Other key drugs include Gilead's Harvoni (sofosbuvir and ledipasvir) and AbbVie's Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets ...
Drugs to Watch 2016 - Foresee the next blockbuster drugs! - LinkedIn
The 2016 edition of the annual Drugs to Watch report reveals that seven new drugs expected to enter the market in 2016 are predicted to ...
Top Selling Pharma Drugs in 2016 | Radio Compass Blog
Top 20 drugs by sales ; 4. Remicade. Infliximab ; 5. MabThera/Rituxan. Rituximab ; 6. Revlimid. Lenalidomide ; 7. Avastin. Bevacizumab.
New Drugs From Abbvie Gilead Intercept And Merck Forecast To ...
... To Achieve Blockbuster Status By 2020. Annual 'Drugs to Watch' study spotlights seven emerging blockbusters poised to enter the market in 2016.
New Drugs from Abbvie, Gilead, Intercept and Merck Forecast to ...
Annual 'Drugs to Watch' study spotlights seven emerging blockbusters poised to enter the market in 2016. News provided by. Thomson Reuters. Feb 03, 2016, 12:01 ...
Drugs that made headlines in 2016 | Nature Medicine
Gene therapies featured prominently among this year's newsworthy drugs, some of which have already received a green light from regulatory ...
Which European Blockbusters Topped the Charts in 2016?
Blockbuster drugs are raking in billions each year in sales. We had a look at the top 7 European best-seller drugs of 2016.
The Best Way to Play 2016's Multibillion-Dollar "Blockbuster" Drugs
One of the storied firm's biggest potential winners is a new drug for psoriasis, ixekizumab. Remember, the top-selling drug in the world, Humira ...
3 Potential Blockbuster Drugs Launching in 2016
The past few years have brought some groundbreaking drug launches, such as the record-breaking Gilead Sciences rollout of its hepatitis C ...
The biggest winners and losers in the 2016 game of blockbusters
But it also has the CDK 4/6 cancer drug abemaciclib (another BTD drug) and baricitinib for rheumatoid arthritis on tap for near-term approvals.
Clarivate Identifies Seven Potential Blockbuster Drugs in Annual ...
The Drugs to Watch report highlights experimental treatments with great promise to realize improved patient outcomes and efforts to finance the ...
The Top 15 Best-Selling Drugs of 2016
Alex Philippidis Senior News Editor Genetic Engineering & Biotechnology News. Prospect of Price Curbs May Dent Future Results for Blockbusters.
2016 FDA drug approvals | Nature Reviews Drug Discovery
The agency also approved Merck & Co.'s bezlotoxumab, a pioneering toxin-targeting antibacterial antibody for preventing the recurrence of ...
Seven future blockbuster drugs to look out for in 2019 | pharmaphorum
AbbVie's rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch this year that are expected to make ...
The top 15 blockbuster patent expirations coming this decade
The biggest names set to face generic pressure in the coming years include the top four of the industry's best-selling drugs in 2020: Humira, ...
10 Blockbuster Drugs of the Future | Kiplinger
Verzenio · Eli Lilly ; Epacadostat · Incyte ; Semaglutide · Novo Nordisk · Best Stock in Every State to Buy Now ; Yescarta · Gilead Sciences · 7 Monthly ...